Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, UT MD Anderson Cancer Center, Houston, TX, USA.
Curr Opin Immunol. 2018 Apr;51:197-203. doi: 10.1016/j.coi.2018.04.007. Epub 2018 May 2.
Adoptive Cell Therapy (ACT) has enjoyed a revival in recent years with the approval of CAR T cells for the treatment of patients with B cell malignancies. Advancing the use of adoptively transferred T cells for the treatment of patients with solid tumor and other hematologic malignancies however, will require addressing numerous effector cell intrinsic as well as tumor micro environmental hurdles and exploiting a broader ACT platform that includes not only engineered CAR-T cells, but also other forms of ACT including Endogenous T Cell (ETC) and Tumor-infiltrating Lymphocyte (TIL) therapy. In this review, we open this discussion with some 'points to consider' as a starting point for envisioning more effective strategies that are now feasible because of recent discoveries In immune resistance and the development of enabling technologies to harness the power of tumor - reactive T cells for adoptive cell therapy.
过继细胞疗法（ACT）近年来随着嵌合抗原受体 T 细胞（CAR-T 细胞）获批用于治疗 B 细胞恶性肿瘤而重新受到关注。然而，要将过继转移的 T 细胞用于治疗实体瘤和其他血液系统恶性肿瘤，就需要解决众多效应细胞内在的以及肿瘤微环境障碍，并利用更广泛的 ACT 平台，不仅包括工程 CAR-T 细胞，还包括其他形式的 ACT，包括内源性 T 细胞（ETC）和肿瘤浸润淋巴细胞（TIL）治疗。在这篇综述中，我们首先提出了一些“需要考虑的要点”，作为更有效策略的起点，这些策略现在由于免疫抵抗方面的最新发现和利用肿瘤反应性 T 细胞进行过继细胞疗法的使能技术的发展而成为可能。
